Condition
Breast Cancer, Early-Onset
Total Trials
4
Recruiting
0
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
Early P 1 (1)
P 2 (1)
Trial Status
Active Not Recruiting2
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05659563Phase 2Completed
Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%
NCT05720039Not ApplicableActive Not Recruiting
Robotic vs. Open NSM for Early Stage Breast Cancer
NCT05333874Early Phase 1Active Not RecruitingPrimary
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
NCT04980989Not ApplicableCompletedPrimary
Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software
Showing all 4 trials